MassGeneral Institute for Neurodegenerative Disease

Translating today's discoveries into tomorrow's cures

Facebook icon Twitter Icon

Hyman, Brad, MD, PhD

Biography
Affiliations

Brad Hyman studies the anatomical and molecular basis of dementia in Alzheimer’s disease, and Dementia with Lewy Bodies. His research includes a collaborative of several labs working on different aspects of neurodegenerative disease and dementia. He also has a clinical practice in the Memory and Disorder Unit at the Massachusetts General Hospital devoted towards the care of patients with dementia.

Bacskai, Brian, PhD

Biography
Affiliations

Brian Bacskai uses optical techniques to ask fundamental questions in Alzheimer's disease research. Using the mulitphoton micrsocopy imaging technique, senile plaques of Alzheimer's disease can be detected and characterized in the brains of living transgenic mice. This approach was used to study a way to clear senile plaques based on immunotherapy, as well as to characterize new factors that target amyloid in preclinical development for PET imaging in humans.

Tanzi, Rudolph, PhD

Biography
Affiliations

Rudolph Tanzi is the Vice-Chair of Neurology (Research) at MGH and Director of the Genetics and Aging Research Unit at MIND. He is an elected "Professor Representative" to the MGH Executive Committee on Research and serves as the Chair of the Cure Alzheimer's Fund Research Consortium, for which he spearheads the Alzheimer’s Genome Project.

Cudkowicz, Merit, MD, MSc

Biography
Affiliations

Merit Cudkowicz’s research and clinical activities are dedicated to the study and treatment of patients with neurodegenerative disorders, in particular amyotrophic lateral sclerosis (ALS) and Huntington’s disease (HD). Her clinical research team conducts experimental therapeutic trials of novel agents and biomarker studies in people with ALS and HD.

Parkinson’s Disease

The second most frequently diagnosed neurodegenerative disease after Alzheimer’s Disease is Parkinson’s Disease (PD). PD onset is usually after the age of 60 and affects about five million people globally. This number is expected to keep rising as the population ages... Learn more

Huntington’s Disease

Huntington’s Disease (HD) is one of the more common neurodegenerative diseases with an estimated 250,000 people in the United States either diagnosed with, or at risk for, the disease. The typical age of HD onset is between the ages of 30 and 50, with very rare juvenile onset as young as two years old and the average lifespan once diagnosed with HD is 10-20 years... Learn more

Alzheimer’s Disease

Alzheimer’s Disease (AD) is a neurodegenerative disease affecting approximately 13% of individuals over the age of 65 and nearly one-third of those over 85, making it the most common cause of dementia. Over $200 Billion dollars are spent on Alzheimer care each year... Learn more

Pages